Anagrelide controlled release - AOP Orphan Pharmaceuticals

Drug Profile

Anagrelide controlled release - AOP Orphan Pharmaceuticals

Alternative Names: Anagrelide CR; Anagrelide retard; ANAT2; Anathromb

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator AOP Orphan Pharmaceuticals AG
  • Class 3-ring heterocyclic compounds; Antiplatelets; Imidazoles; Quinazolines; Small molecules
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Essential thrombocythaemia

Most Recent Events

  • 03 Dec 2016 Efficacy and adverse events data from the phase III ARETA trial in Essential thrombocythaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Apr 2015 AOP Orphan completes a phase III TEAM-ET trial for Essential thrombocythaemia in Austria and Lithuania (NCT02076815)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top